This study is testing a new treatment called ASP-1929 photoimmunotherapy for people with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery. This treatment combines an antibody (a protein that targets specific cells) with a special dye. About 24 hours before planned surgery, you would receive ASP-1929 through an IV. The study aims to see how safe ASP-1929 is (looking at side effects) and how well it prevents the cancer from growing for at least six months. This is an early-stage study, and it's currently unclear if it's recruiting new participants.

Study design

This is an open-label Phase II study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 30 participants.

What's involved

You would receive ASP-1929 intravenously (IV) about 24 hours before a planned surgical exploration. This treatment will be given 4 to 10 weeks after your last chemotherapy and radiation.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for treatment-related side effects for up to 28 days after surgery, and for cancer progression for at least 6 months after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.